Work

Abstract 5213: Evaluation of HER2DX risk-score in residual disease (RD) from HER2-positive (HER2+) early breast cancer (EBC) patients (pts) following neoadjuvant trastuzumab and pertuzumab (HP)-based therapy: An exploratory analysis from the PHERGain trial

Year: 2024

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2024-5213

Authors: José Manuel Pérez-García, Fara Brasó-Maristany, Elena Martínez-García, Carmen Mora Gallardo, Eileen Shimizu, Olga Boix Sánchez, Jose Rodríguez-Morató, Mario Mancino, Laia Paré, Guillermo Villacampa, Mercedes Marín-Aguilera, Patricia Galván, Ana Vivancos, Patricia Villagrasa, Joel Parker, Charles M. Perou, Antonio Llombart-Cussac, Javier Cortés, Aleix Prat

Institutions: MedSIR (Spain), Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, Fundació de Recerca Clínic Barcelona-Institut d’Investigacions Biomèdiques August Pi i Sunyer, Vall d'Hebron Institute of Oncology, University of North Carolina at Chapel Hill

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4393092763

Cites:

Cited by:

Related to: 10